SCHEMBL10135258

SCHEMBL10135258

O=C(O)CNc1nc2ccccc2c2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT5 Q9NXA8 2/20 0.51
CSNK2A1 P68400 2/20 0.48
PDE10A Q9Y233 1/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 2/20 0.46
TSHR P16473 2/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 2/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
PKM P14618 1/20 0.45
UBE2N P61088 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RCE1 Q9Y256 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
MAPK1 P28482 1/20 0.44
ACHE P22303 3/20 0.43
APP P05067 2/20 0.43
HPGD P15428 1/20 0.43
KDM4C Q9H3R0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15289670 0.81 SIRT5 (0.77) SIRT5PDE10AKMT2AMAPTTSHR
SCHEMBL1864822 0.79 POLB (0.61) KMT2AMAPTMEN1LMNAALDH1A1
SCHEMBL15347754 0.77 LMNA (0.65) KMT2AMAPTTSHRMEN1LMNA
SCHEMBL9381152 0.71 OPRK1 (0.51) PDE10AALDH1A1KDM4EHPGDKDM4C
SCHEMBL5236710 0.71 OPRK1 (0.73) PDE10AKMT2AMAPTMEN1KDM4E
SCHEMBL23674253 0.70 ACACA (0.53) SIRT5MAPTLMNAALDH1A1KDM4E
SCHEMBL1520512 0.70 HTR1A (0.65) CSNK2A1ACHE
SCHEMBL9828963 0.70 KCNA5 (0.55) MAPTTSHRSMN1; SMN2ACHE
SCHEMBL29362282 0.70 HTR1A (0.65) CSNK2A1ACHE
SCHEMBL16586949 0.70 MAPT (0.44) MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 SIRT5 1895/4885CSNK2A1 680/4885PDE10A 1921/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 SIRT5 1895/4885CSNK2A1 680/4885PDE10A 1921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.